Literature DB >> 12406541

Cellular mechanisms targeted during astrocytoma progression.

V Peter Collins1.   

Abstract

Astrocytomas are the commonest type of primary brain tumour. Four malignancy grades are recognized with very different prognosis. The most malignant and commonest form in adults is called glioblastoma and has a median survival with modern treatment of less than one year. Over the last 20 years, molecular genetic and cell biological data have helped identify some of the genes affected during oncogenesis and progression. This will be briefly reviewed. Many significant observations have been made but we are still far from understanding the neoplastic astrocyte at the molecular level. This is reflected in inconclusive attempts to date to use current molecular knowledge in providing additional prognostic information and in the design of molecular based treatments. However, it seems reasonable to assume that further understanding of oncogenesis and progression at the molecular level will provide a basis for improved clinical assessment and individually tailored treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12406541     DOI: 10.1016/s0304-3835(02)00198-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

Review 1.  In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro.

Authors:  R F Haseloff; I E Blasig; H C Bauer; H Bauer
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

2.  Mahanine, a novel mitochondrial complex-III inhibitor induces G0/G1 arrest through redox alteration-mediated DNA damage response and regresses glioblastoma multiforme.

Authors:  Kaushik Bhattacharya; Arup K Bag; Rakshamani Tripathi; Suman K Samanta; Bikas C Pal; Chandrima Shaha; Chitra Mandal
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

3.  Establishment and characterization of a new human glioblastoma cell line, NYGM.

Authors:  Yoshitsugu Nuki; Shunro Uchinokura; Shiro Miyata; Tsuyoshi Fukushima; Ryouichi Hamasuna; Shinichi Nakano; Shinichiro Wakisaka; Yutaka Akiyama; Hiroshi Itoh; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2004-09       Impact factor: 4.174

4.  Increased resistance of glioma cell lines to extracellular ATP cytotoxicity.

Authors:  Fernanda B Morrone; Ana Paula Horn; Joseli Stella; Fernando Spiller; João J F Sarkis; Christianne G Salbego; Guido Lenz; Ana Maria O Battastini
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

5.  Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes.

Authors:  Thomas S Jacques; Alexander Swales; Monika J Brzozowski; Nico V Henriquez; Jacqueline M Linehan; Zaman Mirzadeh; Catherine O' Malley; Heike Naumann; Arturo Alvarez-Buylla; Sebastian Brandner
Journal:  EMBO J       Date:  2009-11-19       Impact factor: 11.598

Review 6.  Ion channels and amino acid transporters support the growth and invasion of primary brain tumors.

Authors:  Harald Sontheimer
Journal:  Mol Neurobiol       Date:  2004-02       Impact factor: 5.590

7.  Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events.

Authors:  Ramón Martínez
Journal:  J Signal Transduct       Date:  2012-06-18

Review 8.  HGF/MET Signaling in Malignant Brain Tumors.

Authors:  Elizabeth Qian Xu Mulcahy; Rossymar Rivera Colόn; Roger Abounader
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

9.  Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?

Authors:  L Karayan-Tapon; M Wager; J Guilhot; P Levillain; C Marquant; J Clarhaut; V Potiron; J Roche
Journal:  Br J Cancer       Date:  2008-09-09       Impact factor: 7.640

10.  Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas.

Authors:  Zhi-Liang Wang; Chuan-Bao Zhang; Jin-Quan Cai; Qing-Bin Li; Zheng Wang; Tao Jiang
Journal:  J Exp Clin Cancer Res       Date:  2015-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.